Details of the Drug

General Information of Drug (ID: DMOWZ6B)

• Drug Name: Fluconazole
• Synonyms: Afungil; Alflucoz; Baten; Beagyne; Biocanol; Biozolene; Canzol; Cryptal; Diflazon; Diflucan; Dimycon; Elazor; FCZ; FLCZ; Flucazol; FlucoLich; Flucobeta; Fluconazol; Fluconazolum; Flucostat; Flukezol; Flunazul; Flunizol; Fluzone; Forcan; Fuconal; Fungata; Lavisa; Loitin; Mutum; Neofomiral; Oxifugol; Oxifungol; Pritenzol; Solacap; Syscan; TPF; Triflucan; Zemyc; Zoltec; Zonal; AbZ Brand of Fluconazole; Aliud Brand of Fluconazole; Alpharma Brand of Fluconazole; Apo Fluconazole; Apotex Brand of Fluconazole; Armstrong Brand of Fluconazole; Betapharm Brand of Fluconazole; Chemia Brand of Fluconazole; Ct Arzneimittel Brand of Fluconazole; Effik Brand of Fluconazole; Fluc Hexal; Fluconazol AL; Fluconazol AbZ; Fluconazol Isis; Fluconazol Stada; Fluconazol [Spanish]; Fluconazol ratiopharm; Fluconazol von ct; Fluconazolum [Latin]; Hexal Brand of Fluconazole; Lesvi Brand of Fluconazole; Lichtenstein Brand of Fluconazole; Mack Brand of Fluconazole; Pfizer Brand of Fluconazole; Pfleger Brand of Fluconazole; Ratiopharm Brand of Fluconazole; SAT Brand of Fluconazole; Silanes Brand of Fluconazole; Stada Brand of Fluconazole; Vita Brand of Fluconazole; F0677; Fluconazole in combination with MGCD290; UK 49858; UK49858; Alfumet (TN); Apo-Fluconazole; Ct-Arzneimittel Brand of Fluconazole; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; DRG-0005; Diflucan (TN); Fluconazol-Isis; Fluconazol-ratiopharm; Fluconazole & Bovine Lactoferrin; Fluconazole & Human recombinant granulocyte colony stimulating factor; Fluconazole & hGCSF; Fluconazole in dextrose 5% in plastic container; Flucytosine & Nyotran; GL663142 & Fluconazole; KS-1059; Trican (TN); UK-49858; DIFLUCAN IN SODIUM CHLORIDE 0.9%; DIFLUCAN IN SODIUM CHLORIDE 0.9%IN PLASTIC CONTAINER; Fluconazole in sodium chloride 0.9%; Fluconazole in sodium chloride 0.9% in plastic container; Flucytosine & Nyotran(Liposomal Nystatin); XMP.284 & Fluconazole; XMP.366 & Fluconazole; XMP.391 & Fluconazole; Diflucan, Trican, Alfumet, Fluconazole; Fluconazole & MC-510,011; Fluconazole (JAN/USAN/INN); Fluconazole [USAN:INN:BAN:JAN]; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol

Indication

Disease Entry	ICD 11	Status	REF
Cryptococcal meningitis	N.A.	Approved	[1]
Fungal infection	1F29-1F2F	Approved	[2]
Invasive candidiasis	1F23	Approved	[1]
Mycoses	1F2Z	Approved	[1]
Oral candidiasis	1F23.0	Approved	[1]
Autoimmune polyendocrine syndrome type 1	N.A.	Investigative	[1]
Candidemia	1F23.3Y	Investigative	[1]
Esophageal candidiasis	N.A.	Investigative	[1]

• Therapeutic Class: Antifungal Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 306.27
  Logarithm of the Partition Coefficient (xlogp); 0.4
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 7
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
  Bioavailability: The bioavailability of drug is 90% [3]
  Clearance: The renal clearance of drug is 14.7 +/- 3.7 mL/min [3]
  Elimination: In normal volunteers, fluconazole is cleared primarily by renal excretion, with approximately 80% of the administered dose measured in the urine as unchanged drug [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 20 - 50 hours [3]
  Metabolism: The drug is metabolized via the liver [5]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 9.3285 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.89% [7]
  Vd: The volume of distribution (Vd) of drug is 39 L [3]
  Water Solubility: The ability of drug to dissolve in water is measured as 1 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Hypersensitivity	Not Available	ABCB1	OTEJROBO	[8]
Hypersensitivity	Not Available	YBT1	OTPQCBKA	[8]

• Chemical Identifiers:
  Formula: C13H12F2N6O
  IUPAC Name: 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
  Canonical SMILES: C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O
  InChI: InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
  InChIKey: RFHAOTPXVQNOHP-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3365
  ChEBI ID: CHEBI:46081
  CAS Number: 86386-73-4
  DrugBank ID: DB00196
  TTD ID: D09LNI
  VARIDT ID: DR00578
  INTEDE ID: DR0704
  ACDINA ID: D00280
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Cytochrome P450 51 (Candi ERG11)	TTTSOUD	CP51_CANAL	Modulator	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9) Main DME	DE5IED8	CP2C9_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Gene/Protein Processing	[11]
ATP-dependent bile acid permease	OTPQCBKA	YBT1_YEAST	Drug Response	[8]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Drug Response	[8]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Regulation of Drug Effects	[12]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Gene/Protein Processing	[13]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[14]
Lanosterol 14-alpha demethylase (CYP51A1)	OTAYHG9C	CP51A_HUMAN	Drug Response	[15]
Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)	OTZKVLVJ	CP17A_HUMAN	Gene/Protein Processing	[11]
Steroidogenic acute regulatory protein, mitochondrial (STAR)	OTFEZ5AI	STAR_HUMAN	Gene/Protein Processing	[16]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fluconazole

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Pentamidine.	Fungal infection [1F29-1F2F]	[17]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Fluconazole caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[17]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Fluconazole caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[18]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Ketoconazole.	Fungal infection [1F29-1F2F]	[17]

Coadministration of a Drug Treating the Disease Different from Fluconazole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Fluconazole and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[19]
Methylergonovine	DMBEX4O	Moderate	Decreased metabolism of Fluconazole caused by Methylergonovine mediated inhibition of CYP450 enzyme.	Abortion [JA00]	[20]
Tretinoin	DM49DUI	Major	Decreased metabolism of Fluconazole caused by Tretinoin mediated inhibition of CYP450 enzyme.	Acne vulgaris [ED80]	[21]
Glimepiride	DM5FSJA	Major	Decreased metabolism of Fluconazole caused by Glimepiride mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[22]
Repaglinide	DM5SXUV	Moderate	Decreased metabolism of Fluconazole caused by Repaglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[23]
Glibenclamide	DM8JXPZ	Major	Decreased metabolism of Fluconazole caused by Glibenclamide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[22]
Tolazamide	DMIHRNA	Major	Decreased metabolism of Fluconazole caused by Tolazamide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[22]
Nateglinide	DMLK2QH	Moderate	Decreased metabolism of Fluconazole caused by Nateglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[24]
Acetohexamide	DMR6N7H	Major	Decreased metabolism of Fluconazole caused by Acetohexamide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[22]
Glipizide	DMZA5PQ	Major	Decreased metabolism of Fluconazole caused by Glipizide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[22]
Thioguanine	DM7NKEV	Moderate	Increased risk of hepatotoxicity by the combination of Fluconazole and Thioguanine.	Acute myeloid leukaemia [2A60]	[25]
Ivosidenib	DM8S6T7	Major	Decreased metabolism of Fluconazole caused by Ivosidenib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[26]
Midostaurin	DMI6E0R	Moderate	Decreased metabolism of Fluconazole caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[27]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Idarubicin.	Acute myeloid leukaemia [2A60]	[17]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Daunorubicin.	Acute myeloid leukaemia [2A60]	[17]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Arn-509.	Acute myeloid leukaemia [2A60]	[24]
Gilteritinib	DMTI0ZO	Moderate	Decreased metabolism of Fluconazole caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[24]
Terfenadine	DM4KLPT	Major	Decreased metabolism of Fluconazole caused by Terfenadine mediated inhibition of CYP450 enzyme.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[28]
Loratadine	DMF3AN7	Minor	Decreased metabolism of Fluconazole caused by Loratadine mediated inhibition of CYP450 enzyme.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[29]
Tacrine	DM51FY6	Moderate	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Tacrine.	Alzheimer disease [8A20]	[17]
Galantamine	DMEO794	Moderate	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Galantamine.	Alzheimer disease [8A20]	[17]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Rivastigmine.	Alzheimer disease [8A20]	[17]
Donepezil	DMIYG7Z	Minor	Decreased metabolism of Fluconazole caused by Donepezil mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[30]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Fluconazole and Metronidazole.	Amoebiasis [1A36]	[19]
Ranolazine	DM0C9IL	Major	Decreased metabolism of Fluconazole caused by Ranolazine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[31]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Bepridil.	Angina pectoris [BA40]	[17]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Dronedarone.	Angina pectoris [BA40]	[17]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Fluconazole caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[32]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[33]
Buspirone	DMBS632	Moderate	Decreased metabolism of Fluconazole caused by Buspirone mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[34]
Alprazolam	DMC7XDN	Major	Decreased metabolism of Fluconazole caused by Alprazolam mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[35]
Hydroxyzine	DMF8Y74	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[17]
Clobazam - Lundbeck	DMW1OQ0	Moderate	Decreased metabolism of Fluconazole caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[36]
Promazine	DMZAL7W	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Promazine.	Appearance/behaviour symptom [MB23]	[17]
Cilostazol	DMZMSCT	Major	Decreased metabolism of Fluconazole caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[24]
Voriconazole	DMAOL2S	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Voriconazole.	Aspergillosis [1F20]	[37]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Posaconazole.	Aspergillosis [1F20]	[17]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Levalbuterol.	Asthma [CA23]	[38]
Montelukast	DMD157S	Moderate	Decreased metabolism of Fluconazole caused by Montelukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[39]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Terbutaline.	Asthma [CA23]	[40]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Pirbuterol.	Asthma [CA23]	[40]
Isoetharine	DMITSEH	Moderate	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Isoetharine.	Asthma [CA23]	[40]
Budesonide	DMJIBAW	Moderate	Decreased metabolism of Fluconazole caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[41]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Salbutamol.	Asthma [CA23]	[38]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Formoterol.	Asthma [CA23]	[40]
Pimecrolimus	DMZLGRB	Minor	Decreased metabolism of Fluconazole caused by Pimecrolimus mediated inhibition of CYP450 enzyme.	Atopic eczema [EA80]	[42]
Atomoxetine	DM5L6HI	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Atomoxetine.	Attention deficit hyperactivity disorder [6A05]	[17]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[24]
Desipramine	DMT2FDC	Moderate	Decreased metabolism of Fluconazole caused by Desipramine mediated inhibition of CYP450 enzyme.	Attention deficit hyperactivity disorder [6A05]	[43]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[44]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[17]
Erythromycin	DM4K7GQ	Major	Decreased metabolism of Fluconazole caused by Erythromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[24]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Fluconazole and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[17]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[44]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[44]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[44]
Rabeprazole	DMMZXIW	Moderate	Decreased metabolism of Fluconazole caused by Rabeprazole mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[24]
Moxifloxacin	DMU8V4S	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Moxifloxacin.	Bacterial infection [1A00-1C4Z]	[45]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Fluconazole caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Telithromycin.	Bacterial infection [1A00-1C4Z]	[17]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Retigabine.	Behcet disease [4A62]	[17]
Cariprazine	DMJYDVK	Moderate	Decreased metabolism of Fluconazole caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[46]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Fluconazole and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[47]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Loperamide.	Bowel habit change [ME05]	[48]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Eribulin.	Breast cancer [2C60-2C6Y]	[17]
Ixabepilone	DM2OZ3G	Moderate	Decreased metabolism of Fluconazole caused by Ixabepilone mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[49]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Fluconazole caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[50]
HKI-272	DM6QOVN	Major	Decreased metabolism of Fluconazole caused by HKI-272 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[51]
LY2835219	DM93VBZ	Moderate	Decreased metabolism of Fluconazole caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[52]
Esterified estrogens	DM9KZDO	Moderate	Decreased metabolism of Fluconazole caused by Esterified estrogens mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[53]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Fluconazole caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[24]
Quinestrol	DMJ6H1Z	Moderate	Decreased metabolism of Fluconazole caused by Quinestrol mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[53]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Tamoxifen.	Breast cancer [2C60-2C6Y]	[17]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Fluconazole caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[54]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Toremifene.	Breast cancer [2C60-2C6Y]	[17]
Bosutinib	DMTI8YE	Major	Decreased metabolism of Fluconazole caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[19]
Estradiol	DMUNTE3	Moderate	Decreased metabolism of Fluconazole caused by Estradiol mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[53]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Grepafloxacin.	Bronchitis [CA20]	[44]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Sotalol.	Cardiac arrhythmia [BC9Z]	[17]
Dofetilide	DMPN1TW	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Dofetilide.	Cardiac arrhythmia [BC9Z]	[17]
Atorvastatin	DMF28YC	Major	Decreased metabolism of Fluconazole caused by Atorvastatin mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[55]
Macitentan	DMP79A1	Moderate	Decreased metabolism of Fluconazole caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[56]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[40]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[38]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[40]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[40]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[40]
Anisindione	DM2C48U	Major	Decreased metabolism of Fluconazole caused by Anisindione mediated inhibition of CYP450 enzyme.	Coagulation defect [3B10]	[57]
Irinotecan	DMP6SC2	Moderate	Decreased metabolism of Fluconazole caused by Irinotecan mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[17]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Oxaliplatin.	Colorectal cancer [2B91]	[17]
Isoproterenol	DMK7MEY	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Isoproterenol.	Conduction disorder [BC63]	[38]
Drospirenone	DM1A9W3	Moderate	Decreased metabolism of Fluconazole caused by Drospirenone mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[53]
Levonorgestrel	DM1DP7T	Moderate	Decreased metabolism of Fluconazole caused by Levonorgestrel mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[53]
Ulipristal	DMBNI20	Minor	Decreased metabolism of Fluconazole caused by Ulipristal mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[24]
Etonogestrel	DMKA8J4	Moderate	Decreased metabolism of Fluconazole caused by Etonogestrel mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[53]
Levobupivacaine	DM783CH	Moderate	Decreased metabolism of Fluconazole caused by Levobupivacaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[24]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Halothane.	Corneal disease [9A76-9A78]	[17]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Propofol.	Corneal disease [9A76-9A78]	[58]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Sevoflurane.	Corneal disease [9A76-9A78]	[17]
Lidocaine	DML4ZOT	Moderate	Decreased metabolism of Fluconazole caused by Lidocaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[18]
Cocaine	DMSOX7I	Moderate	Decreased metabolism of Fluconazole caused by Cocaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[18]
Ropivacaine	DMSPJG2	Minor	Decreased metabolism of Fluconazole caused by Ropivacaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[59]
Alfentanil	DMVO0UB	Major	Decreased metabolism of Fluconazole caused by Alfentanil mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[60]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Probucol.	Coronary atherosclerosis [BA80]	[17]
Nimodipine	DMQ0RKZ	Moderate	Decreased metabolism of Fluconazole caused by Nimodipine mediated inhibition of CYP450 enzyme.	Coronary vasospastic disease [BA85]	[32]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Methadone.	Cough [MD12]	[17]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Clofazimine.	Crohn disease [DD70]	[61]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Pasireotide.	Cushing syndrome [5A70]	[17]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Osilodrostat.	Cushing syndrome [5A70]	[24]
Ivacaftor	DMZC1HS	Major	Decreased metabolism of Fluconazole caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[24]
Rivaroxaban	DMQMBZ1	Moderate	Decreased metabolism of Fluconazole caused by Rivaroxaban mediated inhibition of CYP450 enzyme.	Deep vein thrombosis [BD71]	[19]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Fluconazole caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[62]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Sertraline.	Depression [6A70-6A7Z]	[17]
Trimipramine	DM1SC8M	Moderate	Decreased metabolism of Fluconazole caused by Trimipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[43]
Imipramine	DM2NUH3	Moderate	Decreased metabolism of Fluconazole caused by Imipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[43]
Fluoxetine	DM3PD2C	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Fluoxetine.	Depression [6A70-6A7Z]	[17]
Nortriptyline	DM4KDYJ	Moderate	Decreased metabolism of Fluconazole caused by Nortriptyline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[43]
Vilazodone	DM4LECQ	Moderate	Decreased metabolism of Fluconazole caused by Vilazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[63]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Fluconazole caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[18]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Escitalopram.	Depression [6A70-6A7Z]	[17]
OPC-34712	DMHG57U	Major	Decreased metabolism of Fluconazole caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[64]
Clomipramine	DMINRKW	Moderate	Decreased metabolism of Fluconazole caused by Clomipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[43]
Trazodone	DMK1GBJ	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Trazodone.	Depression [6A70-6A7Z]	[65]
Amitriptyline	DMK7F9S	Moderate	Decreased metabolism of Fluconazole caused by Amitriptyline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[43]
Amoxapine	DMKITQE	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Amoxapine.	Depression [6A70-6A7Z]	[17]
Mirtazapine	DML53ZJ	Moderate	Decreased metabolism of Fluconazole caused by Mirtazapine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[66]
Protriptyline	DMNHTZI	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Protriptyline.	Depression [6A70-6A7Z]	[17]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Doxepin.	Depression [6A70-6A7Z]	[17]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Maprotiline.	Depression [6A70-6A7Z]	[17]
Venlafaxine	DMR6QH0	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Venlafaxine.	Depression [6A70-6A7Z]	[19]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Fluconazole caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[67]
[3H]estrone-3-sulphate	DMGPF0N	Moderate	Decreased metabolism of Fluconazole caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[68]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[17]
Ospemifene	DMC4GEI	Major	Decreased metabolism of Fluconazole caused by Ospemifene mediated inhibition of CYP450 enzyme.	Dyspareunia [GA12]	[69]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Deutetrabenazine.	Dystonic disorder [8A02]	[70]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Ingrezza.	Dystonic disorder [8A02]	[71]
Diazepam	DM08E9O	Moderate	Decreased metabolism of Fluconazole caused by Diazepam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[72]
Zonisamide	DM0DTF7	Moderate	Decreased metabolism of Fluconazole caused by Zonisamide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[73]
Mephenytoin	DM5UGDK	Major	Decreased metabolism of Fluconazole caused by Mephenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[74]
Ethosuximide	DMDZ9LT	Moderate	Decreased metabolism of Fluconazole caused by Ethosuximide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Tiagabine	DMKSQG0	Moderate	Decreased metabolism of Fluconazole caused by Tiagabine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Fluconazole caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Phenytoin	DMNOKBV	Major	Decreased metabolism of Fluconazole caused by Phenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[74]
Fosphenytoin	DMOX3LB	Major	Decreased metabolism of Fluconazole caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[74]
Brivaracetam	DMSEPK8	Minor	Decreased metabolism of Fluconazole caused by Brivaracetam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Ethotoin	DMXWOCP	Major	Decreased metabolism of Fluconazole caused by Ethotoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[74]
Phenobarbital	DMXZOCG	Minor	Decreased metabolism of Fluconazole caused by Phenobarbital mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[75]
Carbamazepine	DMZOLBI	Moderate	Decreased metabolism of Fluconazole caused by Carbamazepine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Cannabidiol	DM0659E	Minor	Decreased metabolism of Fluconazole caused by Cannabidiol mediated inhibition of CYP450 enzyme.	Epileptic encephalopathy [8A62]	[24]
Nicardipine	DMCDYW7	Moderate	Decreased metabolism of Fluconazole caused by Nicardipine mediated inhibition of CYP450 enzyme.	Essential hypertension [BA00]	[32]
Bay 80-6946	DMLOS5R	Moderate	Decreased metabolism of Fluconazole caused by Bay 80-6946 mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[76]
Tazemetostat	DMWP1BH	Major	Decreased metabolism of Fluconazole caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[77]
Solifenacin	DMG592Q	Moderate	Decreased metabolism of Fluconazole caused by Solifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[78]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Fluconazole caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[79]
Tolterodine	DMSHPW8	Moderate	Decreased metabolism of Fluconazole caused by Tolterodine mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[80]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Fluconazole caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[81]
Dexlansoprazole	DM1DBV5	Moderate	Decreased metabolism of Fluconazole caused by Dexlansoprazole mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[24]
Omeprazole	DM471KJ	Moderate	Decreased metabolism of Fluconazole caused by Omeprazole mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[24]
Pantoprazole	DMSVOCZ	Moderate	Decreased metabolism of Fluconazole caused by Pantoprazole mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[24]
Cisapride	DMY7PED	Major	Decreased metabolism of Fluconazole caused by Cisapride mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[82]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Fluconazole caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[19]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[17]
Avapritinib	DMK2GZX	Major	Decreased metabolism of Fluconazole caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[24]
Colchicine	DM2POTE	Major	Decreased metabolism of Fluconazole caused by Colchicine mediated inhibition of CYP450 enzyme.	Gout [FA25]	[83]
Ergotamine	DMKR3C5	Moderate	Decreased metabolism of Fluconazole caused by Ergotamine mediated inhibition of CYP450 enzyme.	Headache [8A80-8A84]	[84]
Eplerenone	DMF0NQR	Major	Decreased metabolism of Fluconazole caused by Eplerenone mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[85]
Carvedilol	DMHTEAO	Moderate	Decreased metabolism of Fluconazole caused by Carvedilol mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[86]
Torasemide	DMXKJ6C	Moderate	Decreased metabolism of Fluconazole caused by Torasemide mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[87]
Simeprevir	DMLUA9D	Major	Decreased metabolism of Fluconazole caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[19]
Daclatasvir	DMSFK9V	Moderate	Decreased metabolism of Fluconazole caused by Daclatasvir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[19]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Fluconazole and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[88]
MK-1439	DM215WE	Minor	Decreased metabolism of Fluconazole caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[89]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Fluconazole caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Nevirapine	DM6HX9B	Moderate	Decreased metabolism of Fluconazole caused by Nevirapine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Fluconazole caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[90]
Tipranavir	DM8HJX6	Moderate	Decreased metabolism of Fluconazole caused by Tipranavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[91]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[92]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Fluconazole caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[93]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[94]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Rilpivirine	DMJ0QOW	Moderate	Increased metabolism of Fluconazole caused by Rilpivirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[95]
Amprenavir	DMLMXE0	Minor	Decreased metabolism of Fluconazole caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[96]
Maraviroc	DMTL94F	Moderate	Decreased metabolism of Fluconazole caused by Maraviroc mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[97]
Ritonavir	DMU764S	Minor	Decreased metabolism of Fluconazole caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[98]
Simvastatin	DM30SGU	Major	Decreased metabolism of Fluconazole caused by Simvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[55]
Fluvastatin	DM4MDJY	Moderate	Decreased metabolism of Fluconazole caused by Fluvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[99]
Lovastatin	DM9OZWQ	Major	Decreased metabolism of Fluconazole caused by Lovastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[55]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Fluconazole and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[100]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Fluconazole and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[17]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Fluconazole caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[19]
Aliskiren	DM1BV7W	Moderate	Decreased metabolism of Fluconazole caused by Aliskiren mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[17]
Losartan	DM72JXH	Moderate	Decreased metabolism of Fluconazole caused by Losartan mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[101]
Nisoldipine	DM7ISKJ	Moderate	Decreased metabolism of Fluconazole caused by Nisoldipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[32]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Fluconazole caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[32]
Isradipine	DMA5XGH	Moderate	Decreased metabolism of Fluconazole caused by Isradipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[32]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Fluconazole caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[32]
Diltiazem	DMAI7ZV	Moderate	Decreased metabolism of Fluconazole caused by Diltiazem mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[32]
Amlodipine	DMBDAZV	Moderate	Decreased metabolism of Fluconazole caused by Amlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[32]
Felodipine	DMOSW35	Moderate	Decreased metabolism of Fluconazole caused by Felodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[32]
Hydrochlorothiazide	DMUSZHD	Minor	Decreased renal excretion of Fluconazole caused by Hydrochlorothiazide.	Hypertension [BA00-BA04]	[19]
Tolvaptan	DMIWFRL	Moderate	Decreased metabolism of Fluconazole caused by Tolvaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[102]
Fludrocortisone	DMUDIR8	Moderate	Decreased metabolism of Fluconazole caused by Fludrocortisone mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[18]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Fluconazole caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[24]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Fluconazole caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[103]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Fluconazole caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[104]
Suvorexant	DM0E6S3	Major	Decreased metabolism of Fluconazole caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[105]
Ramelteon	DM7IW9J	Moderate	Decreased metabolism of Fluconazole caused by Ramelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[106]
Eszopiclone	DM8RZ9H	Moderate	Decreased metabolism of Fluconazole caused by Eszopiclone mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[107]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Fluconazole caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[108]
ITI-007	DMUQ1DO	Major	Decreased metabolism of Fluconazole caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[109]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[24]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Phenolphthalein.	Irritable bowel syndrome [DD91]	[17]
Eluxadoline	DMYZ0P1	Moderate	Decreased metabolism of Fluconazole caused by Eluxadoline mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[110]
Naloxegol	DML0B41	Major	Decreased metabolism of Fluconazole caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[24]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Fluconazole and Methotrexate.	Leukaemia [2A60-2B33]	[24]
Pemigatinib	DM819JF	Major	Decreased metabolism of Fluconazole caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[24]
Testosterone	DM7HUNW	Moderate	Decreased metabolism of Fluconazole caused by Testosterone mediated inhibition of CYP450 enzyme.	Low bone mass disorder [FB83]	[18]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Crizotinib.	Lung cancer [2C25]	[111]
Brigatinib	DM7W94S	Major	Decreased metabolism of Fluconazole caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[19]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Ceritinib.	Lung cancer [2C25]	[17]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Fluconazole caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[112]
PF-06463922	DMKM7EW	Moderate	Decreased metabolism of Fluconazole caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[113]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Fluconazole caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[114]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Fluconazole caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[115]
Selpercatinib	DMZR15V	Major	Decreased metabolism of Fluconazole caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[24]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Lumefantrine.	Malaria [1F40-1F45]	[19]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Halofantrine.	Malaria [1F40-1F45]	[116]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Chloroquine.	Malaria [1F40-1F45]	[117]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Hydroxychloroquine.	Malaria [1F40-1F45]	[117]
Quinine	DMSWYF5	Moderate	Decreased metabolism of Fluconazole caused by Quinine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[19]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Primaquine.	Malaria [1F40-1F45]	[17]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[24]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Fluconazole and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[118]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Fluconazole and Idelalisib.	Mature B-cell leukaemia [2A82]	[119]
GDC-0199	DMH0QKA	Major	Decreased metabolism of Fluconazole caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[19]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Fluconazole caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[120]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[121]
Acalabrutinib	DM7GCVW	Major	Decreased metabolism of Fluconazole caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[122]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Fluconazole and Clofarabine.	Mature B-cell lymphoma [2A85]	[123]
Ibrutinib	DMHZCPO	Major	Decreased metabolism of Fluconazole caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[124]
Vincristine	DMINOX3	Moderate	Decreased metabolism of Fluconazole caused by Vincristine mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[18]
Ponatinib	DMYGJQO	Moderate	Decreased metabolism of Fluconazole caused by Ponatinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[125]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Vemurafenib.	Melanoma [2C30]	[17]
Selumetinib	DMC7W6R	Major	Decreased metabolism of Fluconazole caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[126]
LGX818	DMNQXV8	Major	Decreased metabolism of Fluconazole caused by LGX818 mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[127]
Estrone	DM5T6US	Moderate	Decreased metabolism of Fluconazole caused by Estrone mediated inhibition of CYP450 enzyme.	Menopausal disorder [GA30]	[53]
Dienestrol	DMBSXI0	Moderate	Decreased metabolism of Fluconazole caused by Dienestrol mediated inhibition of CYP450 enzyme.	Menopausal disorder [GA30]	[68]
Conjugated estrogens	DMLT0E1	Moderate	Decreased metabolism of Fluconazole caused by Conjugated estrogens mediated inhibition of CYP450 enzyme.	Menopausal disorder [GA30]	[53]
Ethinyl estradiol	DMODJ40	Moderate	Decreased metabolism of Fluconazole caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme.	Menopausal disorder [GA30]	[68]
Nitisinone	DMVS9WQ	Moderate	Decreased metabolism of Fluconazole caused by Nitisinone mediated inhibition of CYP450 enzyme.	Metabolism inborn error [5C50]	[17]
Methysergide	DM1EF73	Moderate	Decreased metabolism of Fluconazole caused by Methysergide mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[20]
Dihydroergotamine	DM5IKUF	Moderate	Decreased metabolism of Fluconazole caused by Dihydroergotamine mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[84]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Fluconazole caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[128]
Rimegepant	DMHOAUG	Moderate	Decreased metabolism of Fluconazole caused by Rimegepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[129]
Eletriptan	DMW649X	Moderate	Decreased metabolism of Fluconazole caused by Eletriptan mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[130]
Flibanserin	DM70DTN	Major	Decreased metabolism of Fluconazole caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[131]
Midazolam	DMXOELT	Major	Decreased metabolism of Fluconazole caused by Midazolam mediated inhibition of CYP450 enzyme.	Mood/affect symptom [MB24]	[35]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Panobinostat.	Multiple myeloma [2A83]	[132]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Thalidomide.	Multiple myeloma [2A83]	[19]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Fingolimod.	Multiple sclerosis [8A40]	[17]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Ozanimod.	Multiple sclerosis [8A40]	[133]
Deflazacort	DMV0RNS	Major	Decreased metabolism of Fluconazole caused by Deflazacort mediated inhibition of CYP450 enzyme.	Muscular dystrophy [8C70]	[24]
Rifabutin	DM1YBHK	Moderate	Decreased metabolism of Fluconazole caused by Rifabutin mediated inhibition of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[134]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Romidepsin.	Mycosis fungoides [2B01]	[17]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Fluconazole caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[24]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Nilotinib.	Myeloproliferative neoplasm [2A20]	[17]
Ruxolitinib	DM7Q98D	Major	Decreased metabolism of Fluconazole caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[24]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Fluconazole caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[135]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Fluconazole caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[136]
Modafinil	DMYILBE	Minor	Decreased metabolism of Fluconazole caused by Modafinil mediated inhibition of CYP450 enzyme.	Narcolepsy [7A20]	[19]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Droperidol.	Nausea/vomiting [MD90]	[17]
Prochlorperazine	DM53SRA	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Prochlorperazine.	Nausea/vomiting [MD90]	[17]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Promethazine.	Nausea/vomiting [MD90]	[17]
Palonosetron	DMBHMOX	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Palonosetron.	Nausea/vomiting [MD90]	[17]
Granisetron	DMIUW25	Moderate	Decreased metabolism of Fluconazole caused by Granisetron mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[18]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Dolasetron.	Nausea/vomiting [MD90]	[17]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Ondansetron.	Nausea/vomiting [MD90]	[17]
Entrectinib	DMMPTLH	Major	Decreased metabolism of Fluconazole caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[19]
Sibutramine	DMFJTDI	Minor	Decreased metabolism of Fluconazole caused by Sibutramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[137]
Levomethadyl Acetate	DM06HG5	Major	Decreased metabolism of Fluconazole caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[138]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Lofexidine.	Opioid use disorder [6C43]	[17]
S-297995	DM26IH8	Moderate	Decreased metabolism of Fluconazole caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[24]
Valdecoxib	DMAY7H4	Moderate	Decreased metabolism of Fluconazole caused by Valdecoxib mediated inhibition of CYP450 enzyme.	Osteoarthritis [FA00-FA05]	[139]
Diclofenac	DMPIHLS	Moderate	Decreased metabolism of Fluconazole caused by Diclofenac mediated inhibition of CYP450 enzyme.	Osteoarthritis [FA00-FA05]	[19]
Olaparib	DM8QB1D	Major	Decreased metabolism of Fluconazole caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[19]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Rucaparib.	Ovarian cancer [2C73]	[17]
Dextropropoxyphene	DM23HCX	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Dextropropoxyphene.	Pain [MG30-MG3Z]	[140]
Butorphanol	DM5KYPJ	Major	Decreased metabolism of Fluconazole caused by Butorphanol mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[141]
Buprenorphine	DMPRI8G	Moderate	Decreased metabolism of Fluconazole caused by Buprenorphine mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[142]
Hydrocodone	DMQ2JO5	Major	Decreased metabolism of Fluconazole caused by Hydrocodone mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[143]
Oxycodone	DMXLKHV	Major	Decreased metabolism of Fluconazole caused by Oxycodone mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[19]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Triclabendazole.	Parasitic worm infestation [1F90]	[17]
Istradefylline	DM20VSK	Moderate	Decreased metabolism of Fluconazole caused by Istradefylline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[144]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Pimavanserin.	Parkinsonism [8A00]	[145]
Bromocriptine	DMVE3TK	Moderate	Decreased metabolism of Fluconazole caused by Bromocriptine mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[18]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Apomorphine.	Parkinsonism [8A00]	[17]
Esomeprazole	DM7BN0X	Moderate	Decreased metabolism of Fluconazole caused by Esomeprazole mediated inhibition of CYP450 enzyme.	Peptic ulcer [DA61]	[24]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Famotidine.	Peptic ulcer [DA61]	[19]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[146]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Lefamulin.	Pneumonia [CA40]	[147]
Prednisone	DM2HG4X	Moderate	Decreased metabolism of Fluconazole caused by Prednisone mediated inhibition of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[18]
Betamethasone	DMAHJEF	Moderate	Decreased metabolism of Fluconazole caused by Betamethasone mediated inhibition of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[18]
Hydrocortisone	DMGEMB7	Moderate	Decreased metabolism of Fluconazole caused by Hydrocortisone mediated inhibition of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[18]
Ergonovine	DM0VEC1	Moderate	Decreased metabolism of Fluconazole caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[20]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Fluconazole caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[148]
Ritodrine	DM4V6RL	Moderate	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Ritodrine.	Preterm labour/delivery [JB00]	[40]
Progesterone	DMUY35B	Moderate	Decreased metabolism of Fluconazole caused by Progesterone mediated inhibition of CYP450 enzyme.	Preterm labour/delivery [JB00]	[53]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Degarelix.	Prostate cancer [2C82]	[24]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and ABIRATERONE.	Prostate cancer [2C82]	[24]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Nilutamide.	Prostate cancer [2C82]	[24]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Enzalutamide.	Prostate cancer [2C82]	[24]
Flutamide	DMK0O7U	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Flutamide.	Prostate cancer [2C82]	[24]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Relugolix.	Prostate cancer [2C82]	[24]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of Fluconazole caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[149]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Bicalutamide.	Prostate cancer [2C82]	[24]
Tamsulosin	DM5QF9V	Moderate	Decreased metabolism of Fluconazole caused by Tamsulosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[150]
Silodosin	DMJSBT6	Moderate	Decreased metabolism of Fluconazole caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[151]
Dutasteride	DMQ4TJK	Moderate	Decreased metabolism of Fluconazole caused by Dutasteride mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[152]
Finasteride	DMWV3TZ	Moderate	Decreased metabolism of Fluconazole caused by Finasteride mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[18]
Alfuzosin	DMZVMKF	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Alfuzosin.	Prostate hyperplasia [GA90]	[17]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Levomepromazine.	Psychotic disorder [6A20-6A25]	[17]
Fluphenazine	DMIT8LX	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Fluphenazine.	Psychotic disorder [6A20-6A25]	[17]
Triflupromazine	DMKFQJP	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Triflupromazine.	Psychotic disorder [6A20-6A25]	[17]
Selexipag	DMAHSU0	Moderate	Decreased metabolism of Fluconazole caused by Selexipag mediated inhibition of UGT.	Pulmonary hypertension [BB01]	[19]
Ambrisentan	DMD1QXW	Minor	Decreased metabolism of Fluconazole caused by Ambrisentan mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[153]
Bosentan	DMIOGBU	Moderate	Decreased metabolism of Fluconazole caused by Bosentan mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[19]
Everolimus	DM8X2EH	Major	Decreased metabolism of Fluconazole caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[154]
Axitinib	DMGVH6N	Moderate	Decreased metabolism of Fluconazole caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[24]
Temsirolimus	DMS104F	Moderate	Decreased metabolism of Fluconazole caused by Temsirolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[155]
Sorafenib	DMS8IFC	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Sorafenib.	Renal cell carcinoma [2C90]	[17]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[45]
Meloxicam	DM2AR7L	Moderate	Decreased metabolism of Fluconazole caused by Meloxicam mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[19]
Upadacitinib	DM32B5U	Moderate	Decreased metabolism of Fluconazole caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[156]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Fluconazole caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[157]
Tofacitinib	DMBS370	Major	Decreased metabolism of Fluconazole caused by Tofacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[19]
Dexamethasone	DMMWZET	Moderate	Decreased metabolism of Fluconazole caused by Dexamethasone mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[18]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Fluconazole and Leflunomide.	Rheumatoid arthritis [FA20]	[17]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Quetiapine.	Schizophrenia [6A20]	[17]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Mesoridazine.	Schizophrenia [6A20]	[17]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Thioridazine.	Schizophrenia [6A20]	[17]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Fluconazole caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[158]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Iloperidone.	Schizophrenia [6A20]	[17]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Paliperidone.	Schizophrenia [6A20]	[17]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Haloperidol.	Schizophrenia [6A20]	[17]
Perphenazine	DMA4MRX	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Perphenazine.	Schizophrenia [6A20]	[17]
Chlorpromazine	DMBGZI3	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Chlorpromazine.	Schizophrenia [6A20]	[17]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Clozapine.	Schizophrenia [6A20]	[17]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Trifluoperazine.	Schizophrenia [6A20]	[17]
Ziprasidone	DMM58JY	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Ziprasidone.	Schizophrenia [6A20]	[17]
Risperidone	DMN6DXL	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Risperidone.	Schizophrenia [6A20]	[17]
Olanzapine	DMPFN6Y	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Olanzapine.	Schizophrenia [6A20]	[19]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Amisulpride.	Schizophrenia [6A20]	[19]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Asenapine.	Schizophrenia [6A20]	[17]
Pimozide	DMW83TP	Major	Decreased metabolism of Fluconazole caused by Pimozide mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[19]
Fentanyl	DM8WAHT	Major	Decreased metabolism of Fluconazole caused by Fentanyl mediated inhibition of CYP450 enzyme.	Sensation disturbance [MB40]	[19]
Sufentanil	DMU7YEL	Moderate	Decreased metabolism of Fluconazole caused by Sufentanil mediated inhibition of CYP450 enzyme.	Sensation disturbance [MB40]	[18]
Avanafil	DM75CXN	Major	Decreased metabolism of Fluconazole caused by Avanafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[159]
Tadalafil	DMJZHT1	Moderate	Decreased metabolism of Fluconazole caused by Tadalafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[160]
Vardenafil	DMTBGW8	Moderate	Decreased metabolism of Fluconazole caused by Vardenafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[161]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Fluconazole caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[162]
LDE225	DMM9F25	Major	Decreased metabolism of Fluconazole caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[163]
Gefitinib	DM15F0X	Moderate	Decreased metabolism of Fluconazole caused by Gefitinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[164]
Larotrectinib	DM26CQR	Moderate	Decreased clearance of Fluconazole due to the transporter inhibition by Larotrectinib.	Solid tumour/cancer [2A00-2F9Z]	[19]
Methylprednisolone	DM4BDON	Moderate	Decreased metabolism of Fluconazole caused by Methylprednisolone mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Vinblastine	DM5TVS3	Moderate	Decreased metabolism of Fluconazole caused by Vinblastine mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Ifosfamide	DMCT3I8	Moderate	Decreased metabolism of Fluconazole caused by Ifosfamide mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Docetaxel	DMDI269	Moderate	Decreased metabolism of Fluconazole caused by Docetaxel mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[165]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Fluconazole and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[24]
Armodafinil	DMGB035	Minor	Decreased metabolism of Fluconazole caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Fluconazole and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[17]
Etoposide	DMNH3PG	Moderate	Decreased metabolism of Fluconazole caused by Etoposide mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Epirubicin	DMPDW6T	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Prednisolone	DMQ8FR2	Moderate	Decreased metabolism of Fluconazole caused by Prednisolone mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[24]
Norethindrone	DMTY169	Moderate	Decreased metabolism of Fluconazole caused by Norethindrone mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[68]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Fluconazole caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[166]
Doxorubicin	DMVP5YE	Moderate	Decreased metabolism of Fluconazole caused by Doxorubicin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Vinorelbine	DMVXFYE	Moderate	Decreased metabolism of Fluconazole caused by Vinorelbine mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Pitolisant.	Somnolence [MG42]	[17]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[17]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Fluconazole and Naltrexone.	Substance abuse [6C40]	[167]
Warfarin	DMJYCVW	Major	Decreased metabolism of Fluconazole caused by Warfarin mediated inhibition of CYP450 enzyme.	Supraventricular tachyarrhythmia [BC81]	[57]
Ibutilide	DMKXY2R	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Ibutilide.	Supraventricular tachyarrhythmia [BC81]	[17]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Fluconazole and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[17]
Zithromax	DMN4H2O	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Zithromax.	Syphilis [1A61-1A6Z]	[17]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Fluconazole caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[168]
As-1670542	DMV05SW	Major	Decreased metabolism of Fluconazole caused by As-1670542 mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[169]
Anagrelide	DMSQ8MD	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Anagrelide.	Thrombocytosis [3B63]	[17]
Apixaban	DM89JLN	Moderate	Decreased metabolism of Fluconazole caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[24]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Fluconazole caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[24]
Dicumarol	DMFQCB1	Major	Decreased metabolism of Fluconazole caused by Dicumarol mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[170]
Clopidogrel	DMOL54H	Major	Decreased metabolism of Fluconazole caused by Clopidogrel mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[171]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Lenvatinib.	Thyroid cancer [2D10]	[17]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Cabozantinib.	Thyroid cancer [2D10]	[24]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Papaverine.	Tonus and reflex abnormality [MB47]	[172]
Tizanidine	DMR2IQ4	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Tizanidine.	Tonus and reflex abnormality [MB47]	[17]
Trimetrexate	DMDEA85	Minor	Decreased metabolism of Fluconazole caused by Trimetrexate mediated inhibition of CYP450 enzyme.	Toxoplasmosis [1F57]	[173]
Sirolimus	DMGW1ID	Major	Decreased metabolism of Fluconazole caused by Sirolimus mediated inhibition of CYP450 enzyme.	Transplant rejection [NE84]	[174]
Tacrolimus	DMZ7XNQ	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Tacrolimus.	Transplant rejection [NE84]	[174]
Tolbutamide	DM02AWV	Major	Decreased metabolism of Fluconazole caused by Tolbutamide mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[22]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Fluconazole caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[24]
Chlorpropamide	DMPHZQE	Major	Decreased metabolism of Fluconazole caused by Chlorpropamide mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[22]
Diethylstilbestrol	DMN3UXQ	Moderate	Decreased metabolism of Fluconazole caused by Diethylstilbestrol mediated inhibition of CYP450 enzyme.	Vaginitis [GA02]	[53]
Fexofenadine	DM17ONX	Minor	Decreased clearance of Fluconazole due to the transporter inhibition by Fexofenadine.	Vasomotor/allergic rhinitis [CA08]	[175]
Astemizole	DM2HN6Q	Major	Decreased metabolism of Fluconazole caused by Astemizole mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[28]
Triamcinolone	DM98IXF	Moderate	Decreased metabolism of Fluconazole caused by Triamcinolone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[18]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[140]
Fluticasone	DMGCSVF	Moderate	Decreased metabolism of Fluconazole caused by Fluticasone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[19]
Disopyramide	DM5SYZP	Major	Increased risk of prolong QT interval by the combination of Fluconazole and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[17]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Propafenone.	Ventricular tachyarrhythmia [BC71]	[17]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Fluconazole and Flecainide.	Ventricular tachyarrhythmia [BC71]	[17]
Amiodarone	DMUTEX3	Major	Decreased metabolism of Fluconazole caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[176]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Quinoline yellow WS	E00309	24671	Colorant
Silotermo carmine G	E00611	135487652	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Dextrose monohydrate	E00538	22814120	Binding agent; Diluent; Flavoring agent; Tonicity agent
Eisenoxyd	E00585	56841934	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium citrate dihydrate	E00369	71474	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sucrose 1,6-distearate	E00593	71587490	Dispersing agent; Emulsifying agent; Modified-release agent; Solubilizing agent; Surfactant; lubricant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Fluconazole 100 mg tablet	100 mg	Oral Tablet	Oral
Fluconazole 150 mg tablet	150 mg	Oral Tablet	Oral
Fluconazole 50 mg tablet	50 mg	Oral Tablet	Oral
Fluconazole 200 mg tablet	200 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Fluconazole FDA Label
• [2] Fluconazole use as an important risk factor in the emergence of fluconazole-resistant Candida glabrata fungemia. Arch Intern Med. 2009 Aug 10;169(15):1444-5; author reply 1445.
• [3] FDA Approved Drug Products: Diflucan (fluconazole)
• [4] BDDCS applied to over 900 drugs
• [5] Pichette V, du Souich P: Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. J Am Soc Nephrol. 1996 Feb;7(2):345-9.
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [8] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000 Jun;56(3):225-9.
• [11] The classic azole antifungal drugs are highly potent endocrine disruptors in vitro inhibiting steroidogenic CYP enzymes at concentrations lower than therapeutic Cmax. Toxicology. 2019 Sep 1;425:152247. doi: 10.1016/j.tox.2019.152247. Epub 2019 Jul 19.
• [12] [Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method]. Yao Xue Xue Bao. 2007 Jun;42(6):589-94.
• [13] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [14] CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther. 2005 Jul;314(1):180-90.
• [15] Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
• [16] Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol. 2012 Dec;215(3):403-12. doi: 10.1530/JOE-12-0310. Epub 2012 Oct 4.
• [17] Canadian Pharmacists Association.
• [18] Assan R, Fredj G, Larger E, Feutren G, Bismuth H "FK 506/fluconazole interaction enhances FK 506 nephrotoxicity." Diabete Metab 20 (1994): 49-52. [PMID: 7520007]
• [19] Cerner Multum, Inc. "Australian Product Information.".
• [20] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207. [PMID: 9145904]
• [21] Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
• [22] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [23] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
• [24] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [25] Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
• [26] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [27] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
• [28] Ament PW, Paterson A "Drug interactions with the nonsedating antihistamines." Am Fam Physician 56 (1997): 223. [PMID: 9225677]
• [29] Product Information. Claritin (loratadine). Schering Laboratories, Kenilworth, NJ.
• [30] Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
• [31] Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
• [32] Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
• [33] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [34] Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ "Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole." Clin Pharmacol Ther 62 (1997): 348-54. [PMID: 9333111]
• [35] Ahonen J, Olkkola KT, Neuvonen PJ "Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers." Br J Clin Pharmacol 40 (1995): 270-2. [PMID: 8527290]
• [36] Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
• [37] Product Information. Diflucan (fluconazole). Roerig Division, New York, NY.
• [38] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [39] Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT "Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast." Clin Pharmacol Ther (2010):. [PMID: 20592724]
• [40] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [41] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
• [42] Product Information. Elidel (pimecrolimus topical). Novartis Pharmaceuticals, East Hanover, NJ.
• [43] Dorsey ST, Biblio LA "Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline." Am J Emerg Med 18 (2000): 227-9. [PMID: 10750939]
• [44] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [45] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [46] Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
• [47] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [48] Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
• [49] Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
• [50] Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [51] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
• [52] Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
• [53] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
• [54] Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
• [55] Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20. [PMID: 17368833]
• [56] Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
• [57] Baciewicz AM, Menke JJ, Bokar JA, Baud EB "Fluconazole-warfarin interaction." Ann Pharmacother 28 (1994): 1111. [PMID: 7803894]
• [58] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [59] Ekstrom G, Gunnarsson UB "Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes." Drug Metab Dispos 24 (1996): 955-61. [PMID: 8886604]
• [60] Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
• [61] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [62] Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
• [63] Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
• [64] Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
• [65] Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
• [66] Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H "Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients." Biochem Pharmacol 93 (2015): 104-9. [PMID: 25475885]
• [67] Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
• [68] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
• [69] Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
• [70] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [71] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [72] Ahonen J, Olkkola KT, Neuvonen PJ "The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam." Fundam Clin Pharmacol 10 (1996): 314-8. [PMID: 8836707]
• [73] Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
• [74] Blum RA, Wilton JH, Hilligoss DM, et al "Effect of fluconazole on the disposition of phenytoin." Clin Pharmacol Ther 49 (1991): 420-5. [PMID: 2015731]
• [75] Klotz U "The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications." Clin Pharmacokinet 46 (2007): 271-9. [PMID: 17375979]
• [76] Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
• [77] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [78] Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
• [79] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [80] Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
• [81] Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
• [82] Bedford TA, Rowbotham DJ "Cisapride: drug interactions of clinical significance." Drug Saf 15 (1996): 167-75. [PMID: 8879971]
• [83] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
• [84] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
• [85] Product Information. Inspra (eplerenone). Searle, Chicago, IL.
• [86] Product Information. Coreg (carvedilol). SmithKline Beecham, Philadelphia, PA.
• [87] Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ "Human hepatic cytochrome p450 2c9 catalyzes the rate-limiting pathway of torsemide metabolism." J Pharmacol Exp Ther 272 (1995): 1076-81. [PMID: 7891318]
• [88] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [89] Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
• [90] Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
• [91] Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
• [92] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [93] Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
• [94] Koks CH, Crommentuyn KM, Hoetelmans RM, et al. "The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals." Br J Clin Pharmacol 51 (2001): 631-5. [PMID: 11422025]
• [95] Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
• [96] Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
• [97] Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [98] Cato A 3rd, Cao G, Hsu A, Cavanaugh J, Leonard J, Granneman R "Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir." Drug Metab Dispos 25 (1997): 1104-6. [PMID: 9311629]
• [99] Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ "Effect of fluconazole on plasma fluvastatin and pravastatin concentrations." Eur J Clin Pharmacol 56 (2000): 225-9. [PMID: 10952477]
• [100] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [101] Kazierad DJ, Martin DE, Tenero D, et al. "Fluconazole significantly alters the pharmacokinetics of losartan but not eprosartan." Clin Pharmacol Ther 61 (1997): 203. [PMID: 9357393]
• [102] Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
• [103] Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
• [104] Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [105] Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
• [106] Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
• [107] Alderman CP, Gebauer MG, Gilbert AL, Condon JT "Possible interaction of zopiclone and nefazodone." Ann Pharmacother 35 (2001): 1378-80. [PMID: 11724087]
• [108] Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
• [109] Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
• [110] Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
• [111] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [112] Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
• [113] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [114] Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
• [115] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [116] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [117] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [118] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [119] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [120] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [121] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [122] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [123] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [124] Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
• [125] Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [126] Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [127] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [128] Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
• [129] Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
• [130] Product Information. Relpax (eletriptan). Pfizer U.S. Pharmaceuticals, New York, NY.
• [131] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [132] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [133] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [134] Jordan MK, Polis MA, Kelly G, Narang PK, Masur H, Piscitelli SC "Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics." Antimicrob Agents Chemother 44 (2000): 2170-72. [PMID: 10898693]
• [135] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [136] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [137] Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
• [138] Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
• [139] Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
• [140] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
• [141] Product Information. Butorphanol Tartrate (butorphanol). Apotex Corporation, Weston, FL.
• [142] Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
• [143] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
• [144] Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
• [145] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [146] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [147] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [148] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [149] Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
• [150] Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
• [151] Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
• [152] Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
• [153] Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
• [154] Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
• [155] Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
• [156] Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
• [157] Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
• [158] Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
• [159] Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
• [160] Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
• [161] Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
• [162] Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
• [163] Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
• [164] Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
• [165] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
• [166] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
• [167] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [168] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [169] Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
• [170] Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991): 585-6. [PMID: 1750792]
• [171] Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
• [172] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [173] Product Information. Neutrexin (trimetrexate). US Bioscience, West Conshohocken, PA.
• [174] Albengres E, Le Louet H, Tillement JP "Systemic antifungal agents. Drug interactions of clinical significance." Drug Saf 18 (1998): 83-97. [PMID: 9512916]
• [175] Product Information. Allegra (fexofenadine). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [176] Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y "Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions." Drug Metab Dispos 21 (1993): 978-85. [PMID: 7905403]